Form 4: Vertex Pharmaceuticals Executive Trades VRTX Stock
Statement of Changes in Beneficial Ownership
Vertex Pharmaceuticals EVP and CMO Carmen Bozic reported transactions involving company common stock under a pre-arranged trading plan.
Summary
- Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, reported a transaction on May 29, 2026.
- The transaction involved the disposal of 1,974 shares of common stock at a price of $450 per share.
- This disposal was made pursuant to a Rule 10b5-1 trading plan established on November 20, 2025.
- Following the transaction, Ms. Bozic beneficially owns 22,760 shares of Vertex Pharmaceuticals common stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine transaction under a pre-established trading plan by an executive, with no immediate indication of positive or negative company performance.
Negatives
- Disposal of 1,974 shares of common stock by a key executive.
Future Outlook
The filing does not contain forward-looking statements or guidance.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into executive stock dealings. The use of a Rule 10b5-1 plan indicates a pre-planned strategy for stock sales, often used to avoid concerns about insider trading.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan | Transaction executed under a company-approved trading plan established under Rule 10b5-1. | 11/20/2025 | Demonstrates adherence to established corporate governance policies for executive stock transactions, mitigating potential insider trading concerns. |
Stakeholder Impact
- Shareholders: The disposal of shares by an executive may be observed, but the use of a Rule 10b5-1 plan suggests it was pre-planned and not necessarily a reflection of negative sentiment towards the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 11/20/2025 | Date trading plan under Rule 10b5-1 was entered into. |
| 05/29/2026 | Transaction date for the disposal of common stock. |
| 06/02/2026 | Date the statement was signed. |
Keywords
Vertex Pharmaceuticals, VRTX, Form 4, Insider Trading, Rule 10b5-1, Stock Transaction, Carmen Bozic, EVP and CMO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.